WO2021159130A3 - Vaccins a arn de coronavirus et procédés d'utilisation - Google Patents

Vaccins a arn de coronavirus et procédés d'utilisation Download PDF

Info

Publication number
WO2021159130A3
WO2021159130A3 PCT/US2021/032609 US2021032609W WO2021159130A3 WO 2021159130 A3 WO2021159130 A3 WO 2021159130A3 US 2021032609 W US2021032609 W US 2021032609W WO 2021159130 A3 WO2021159130 A3 WO 2021159130A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
rna vaccines
coronavirus rna
vaccines
coronavirus
Prior art date
Application number
PCT/US2021/032609
Other languages
English (en)
Other versions
WO2021159130A2 (fr
Inventor
Hamilton BENNETT
Guillaume Stewart-Jones
Elisabeth NARAYANAN
Andrea Carfi
Mihir METKAR
Vladimir PRESNYAK
Barney S. Graham
Kizzmekia S. Corbett
Original Assignee
Modernatx, Inc.
The United States Of America, As Represented By The Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx, Inc., The United States Of America, As Represented By The Department Of Health And Human Services filed Critical Modernatx, Inc.
Publication of WO2021159130A2 publication Critical patent/WO2021159130A2/fr
Publication of WO2021159130A3 publication Critical patent/WO2021159130A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

L'invention concerne des compositions de vaccins à acide ribonucléique messager (ARNm) de SARS-CoV-2, ainsi que des méthodes d'utilisation des vaccins.
PCT/US2021/032609 2020-05-15 2021-05-14 Vaccins a arn de coronavirus et procédés d'utilisation WO2021159130A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063025918P 2020-05-15 2020-05-15
US63/025,918 2020-05-15
US202063028424P 2020-05-21 2020-05-21
US63/028,424 2020-05-21

Publications (2)

Publication Number Publication Date
WO2021159130A2 WO2021159130A2 (fr) 2021-08-12
WO2021159130A3 true WO2021159130A3 (fr) 2021-11-18

Family

ID=76284236

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/032609 WO2021159130A2 (fr) 2020-05-15 2021-05-14 Vaccins a arn de coronavirus et procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2021159130A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017031232A1 (fr) 2015-08-17 2017-02-23 Modernatx, Inc. Procédés de préparation de particules et compositions associées
EP4011451A1 (fr) 2015-10-22 2022-06-15 ModernaTX, Inc. Vaccins contre le virus respiratoire
EP3364981A4 (fr) 2015-10-22 2019-08-07 ModernaTX, Inc. Vaccin contre le cytomégalovirus humain
CN116837052A (zh) 2016-09-14 2023-10-03 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
JP6980780B2 (ja) 2016-10-21 2021-12-15 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
MA52262A (fr) 2017-03-15 2020-02-19 Modernatx Inc Vaccin à large spectre contre le virus de la grippe
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
US11905525B2 (en) 2017-04-05 2024-02-20 Modernatx, Inc. Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
WO2019036682A1 (fr) 2017-08-18 2019-02-21 Modernatx, Inc. Variants d'arn polymérase
EP3668979A4 (fr) 2017-08-18 2021-06-02 Modernatx, Inc. Procédés pour analyse par clhp
EP3668977A4 (fr) 2017-08-18 2021-04-21 Modernatx, Inc. Procédés analytiques par hplc
WO2019046809A1 (fr) 2017-08-31 2019-03-07 Modernatx, Inc. Procédés de fabrication de nanoparticules lipidiques
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
GB2594365B (en) 2020-04-22 2023-07-05 BioNTech SE Coronavirus vaccine
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
JP2023546534A (ja) 2020-10-12 2023-11-02 ライフ・テクノロジーズ・アクシェセルスカプ 生体細胞と共に使用するための磁性粒子処理システム及び関連する方法
GB202017751D0 (en) 2020-11-10 2020-12-23 Life Tech As Sample protection
AU2021385572A1 (en) 2020-11-25 2023-06-22 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
US11524023B2 (en) * 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
AU2022270658A1 (en) 2021-05-04 2023-11-16 BioNTech SE Technologies for early detection of variants of interest
WO2022268916A2 (fr) 2021-06-23 2022-12-29 Ose Immunotherapeutics Vaccin peptidique pan-coronavirus
CA3132191A1 (fr) * 2021-09-28 2023-03-28 Providence Therapeutics Holdings Inc. Compositions et methodes de prevention et/ou de traitement de la covid-19
WO2023098679A1 (fr) * 2021-11-30 2023-06-08 石药集团巨石生物制药有限公司 Nouveau vaccin à arnm de coronavirus dirigé contre des souches mutantes
CN117580587A (zh) * 2021-12-03 2024-02-20 苏州艾博生物科技有限公司 基于源自SARS-CoV-2奥密克戎毒株的序列的冠状病毒核酸疫苗
CN115813848B (zh) * 2021-12-10 2023-08-08 上海臻上医药科技有限公司 微针注射mRNA编码双特异性抗体药物的试剂、方法和应用
WO2023121264A1 (fr) * 2021-12-20 2023-06-29 아이진 주식회사 Composition de vaccin pour variant du sars-cov-2, et son utilisation
EP4242308A1 (fr) * 2022-01-27 2023-09-13 Shenzhen Rhegen Biotechnology Co., Ltd. Vaccin à arnm contre le sras-cov-2, son procédé de préparation et son utilisation
KR20230144421A (ko) * 2022-04-07 2023-10-16 엠큐렉스 주식회사 사스-코로나바이러스 2 감염증에 대한 rna 백신
CN116925195A (zh) * 2022-04-22 2023-10-24 仁景(苏州)生物科技有限公司 一种基于新型冠状病毒的mRNA疫苗
GB2618818A (en) * 2022-05-18 2023-11-22 Phion Therapeutics Ltd Vaccine
KR20230167309A (ko) 2022-05-31 2023-12-08 경상국립대학교산학협력단 신규한 변형 폴리아데닌 서열 및 이의 용도
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018081318A1 (fr) * 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéines de spicule de coronavirus de préfusion et utilisation associée
US20190240317A1 (en) * 2015-10-22 2019-08-08 Modernatx, Inc. Hpiv3 rna vaccines
WO2021154763A1 (fr) * 2020-01-28 2021-08-05 Modernatx, Inc. Vaccins à arn contre le coronavirus

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
EP2305699B1 (fr) 2001-06-05 2014-08-13 CureVac GmbH ARNm stabilisée avec un contenu augmenté en G/C et optimisée pour la translation dans ses zones codées pour la vaccination contre la trypanosomiase, la leishmaniose et la toxoplasmose
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
JP2010531640A (ja) 2007-06-29 2010-09-30 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション 毒性化合物の分解方法
DK3156414T3 (da) 2007-09-26 2020-03-09 Intrexon Corp Syntetisk 5'utrs ekspressionsvektorer og fremgangsmåder til øgning af transgen ekspression
CA2904904A1 (fr) 2007-12-11 2009-06-18 The Scripps Research Institute Compositions et procedes concernant des elements activateurs de traduction de l'arnm
CN102695525B (zh) 2009-07-31 2016-01-20 埃泽瑞斯公司 用于蛋白质表达的具有未修饰和修饰核苷酸的组合的rna
TR201910686T4 (tr) 2011-06-08 2019-08-21 Translate Bio Inc Mrna iletimine yönelik lipit nanopartikül bileşimleri ve yöntemler.
MX2014015041A (es) 2012-06-08 2015-06-17 Shire Human Genetic Therapies Administración pulmonar de arnm a células objetivo no pulmonares.
WO2014071963A1 (fr) 2012-11-09 2014-05-15 Biontech Ag Procédé pour l'expression d'arn cellulaire
LT2970456T (lt) 2013-03-14 2021-08-10 Translate Bio, Inc. Būdai ir kompozicijos, skirti mrnr koduojamų antikūnų pristatymui
ES2967701T3 (es) 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
WO2015024667A1 (fr) 2013-08-21 2015-02-26 Curevac Gmbh Procédé pour augmenter l'expression de protéines codées par l'arn
CA2925021A1 (fr) 2013-11-01 2015-05-07 Curevac Ag Arn modifie a proprietes immunostimulantes reduites
WO2015101415A1 (fr) 2013-12-30 2015-07-09 Curevac Gmbh Molécules d'acides nucléiques artificielles
BR112016014462A2 (pt) 2013-12-30 2017-10-24 Curevac Ag moléculas de ácido nucleico artificiais
KR101793271B1 (ko) 2015-07-09 2017-11-20 인텔렉추얼디스커버리 주식회사 공기압을 이용한 휴대용 살균수 스프레이건
US20210206818A1 (en) 2016-01-22 2021-07-08 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
CN116837052A (zh) 2016-09-14 2023-10-03 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
WO2019036682A1 (fr) 2017-08-18 2019-02-21 Modernatx, Inc. Variants d'arn polymérase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190240317A1 (en) * 2015-10-22 2019-08-08 Modernatx, Inc. Hpiv3 rna vaccines
WO2018081318A1 (fr) * 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéines de spicule de coronavirus de préfusion et utilisation associée
WO2021154763A1 (fr) * 2020-01-28 2021-08-05 Modernatx, Inc. Vaccins à arn contre le coronavirus

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) - Tabular View - ClinicalTrials.gov", 25 February 2020 (2020-02-25), XP055826271, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/record/NCT04283461> [retrieved on 20210721] *
CHAKRABORTY SABORNI ET AL: "SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM , NL, vol. 172, 20 January 2021 (2021-01-20), pages 314 - 338, XP086565402, ISSN: 0169-409X, [retrieved on 20210120], DOI: 10.1016/J.ADDR.2021.01.014 *
CHARY MICHAEL A ET AL: "COVID-19: Therapeutics and Their Toxicities", JOURNAL OF MEDICAL TOXICOLOGY, SPRINGER US, NEW YORK, vol. 16, no. 3, 30 April 2020 (2020-04-30), pages 284 - 294, XP037165169, ISSN: 1556-9039, [retrieved on 20200430], DOI: 10.1007/S13181-020-00777-5 *
CORBETT KIZZMEKIA S ET AL: "SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness", NATURE, MACMILLAN JOURNALS LTD., ETC, LONDON, vol. 586, no. 7830, 5 August 2020 (2020-08-05), pages 567 - 571, XP037277114, ISSN: 0028-0836, [retrieved on 20200805], DOI: 10.1038/S41586-020-2622-0 *
DATABASE EMBL [online] EBI; 15 January 2020 (2020-01-15), ZHANG Y.-Z. ET AL: "Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome.", XP055796635, Database accession no. MN908947 *
FUZHOU WANG ET AL: "An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development", MEDICAL SCIENCE MONITOR, vol. 26, 21 April 2020 (2020-04-21), PL, pages e924700 - 1, XP055735156, ISSN: 1234-1010, DOI: 10.12659/MSM.924700 *
LISA A. JACKSON ET AL: "An mRNA Vaccine against SARS-CoV-2 - Preliminary Report", THE NEW ENGLAND JOURNAL OF MEDICINE, 14 July 2020 (2020-07-14), US, XP055715132, ISSN: 0028-4793, DOI: 10.1056/NEJMoa2022483 *
PBR STAFF WRITER: "Moderna doses first patient with mRNA-1273 in coronavirus vaccine trial", 17 March 2020 (2020-03-17), XP055826029, Retrieved from the Internet <URL:https://www.pharmaceutical-business-review.com/news/moderna-mrna-1273-coronavirus-trial> [retrieved on 20210720] *
ROBERT N. KIRCHDOERFER ET AL: "Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis", SCIENTIFIC REPORTS, vol. 8, no. 1, 24 October 2018 (2018-10-24), XP055734535, DOI: 10.1038/s41598-018-34171-7 *
TU YUNG-FANG ET AL: "A Review of SARS-CoV-2 and the Ongoing Clinical Trials", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 7, 10 April 2020 (2020-04-10), pages 2657, XP055788511, DOI: 10.3390/ijms21072657 *
XIA JIA ET AL: "Towards an effective mRNA vaccine against 2019-nCoV: demonstration of virus-like particles expressed from an modified mRNA cocktail", 25 February 2020 (2020-02-25), XP055820076, Retrieved from the Internet <URL:http://www.chinaxiv.org/user/download.htm?id=30257&filetype=pdf> [retrieved on 20210701] *

Also Published As

Publication number Publication date
WO2021159130A2 (fr) 2021-08-12

Similar Documents

Publication Publication Date Title
WO2021159130A3 (fr) Vaccins a arn de coronavirus et procédés d&#39;utilisation
MX2022009280A (es) Vacunas de arn contra el coronavirus.
WO2021155243A8 (fr) Compositions d&#39;immunisation contre le virus respiratoire
MX2022009707A (es) Vacunas de dominio de arnm contra el sars-cov-2.
WO2022221359A8 (fr) Vaccins à arnm du virus d&#39;epstein-barr
WO2023283642A8 (fr) Vaccins concatémères à coronavirus pan-humain
PH12018500855A1 (en) Herpes simplex virus vaccine
MX2022006603A (es) Vacuna contra el virus de la influenza de amplio espectro.
PH12018500856A1 (en) Respiratory syncytial virus vaccine
MX2023005697A (es) Composiciones y metodos para la estabilizacion de vacunas de arnm en nanoparticulas lipidicas.
WO2018183808A9 (fr) Thérapeutique antivirale
WO2010019262A3 (fr) Vaccin polyvalent
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
WO2023107999A3 (fr) Vaccins à arnm contre le virus de l&#39;herpès simplex
MX2023005696A (es) Composiciones de lnp que comprenden arn y metodos para preparar, almacenar y usar las mismas.
WO2022103929A3 (fr) Acides nucléiques, protéines et vaccins contre le sars-cov-2
EP3587593A3 (fr) Compositions, procédés et trousses pour la détection d&#39;acides nucléiques du virus de l&#39;herpès simplex
MX2010005094A (es) Complejo de acido nucleico y composicion de suministro de acido nucleico.
ATE454164T1 (de) Francisella-stamm für lebenden impfstoff
DE60325838D1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
WO2022218891A3 (fr) Compositions d&#39;arn comprenant une substance tampon et procédés de préparation, de stockage et d&#39;utilisation de celles-ci
WO2023114936A3 (fr) Variants de subtilisine et procédés d&#39;utilisation
MX2022012561A (es) Composiciones y metodos para silenciar la expresion de la subunidad alfa tipo ix dependiente del voltaje del canal de sodio (scn9a).
AR121205A1 (es) Vacunas de arn contra el coronavirus
WO2023092100A3 (fr) Méthodes d&#39;administration de vaccins chimériques

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21730424

Country of ref document: EP

Kind code of ref document: A2